Xenon Pharmaceuticals Inc.
XENENasdaq
$68.26
↑ +1.9%Jul 17 close · end-of-day
Price
1Y↑ +115.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.0B
Enterprise Value
$4.9B
P/E
—
P/S
—
P/B
4.5
EV/EBITDA
—
PEG
—
FCF Yield
-5.1%
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$383.2M
Free Cash Flow (TTM)
-$307.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-28.6%
ROIC
-134.1%
Debt / Equity
—
Net Cash
$1.1B
Return 1Y
+112.5%
Company profile
Xenon Pharmaceuticals Inc. engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy. XEN007, a central nervous system-acting calcium channel modulator, is in Phase II clinical trials.
- CEO
- Ian C. Mortimer
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 210
- Headquarters
- British Columbia
- Website
- xenon-pharma.com
Management & directors
- Difabio AndreaChief Legal Officer
- Kenney Christopher JohnChief Medical Officer
- Mortimer IanPRESIDENT, CEO & INTERIM CFO
Roles derived from SEC Form 4 filings.
Earnings
XENE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$1.17↑ +41.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $32.2M | $18.4M | $9.4M | $0.00 | $0.00 | $7.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$31.3M | -$79.0M | -$129.1M | -$214.1M | -$279.3M | -$373.1M |
| Net income | -$28.8M | -$78.9M | -$125.4M | -$182.4M | -$234.3M | -$345.9M |
| Diluted EPS | -$0.81 | -$1.77 | -$2.06 | -$2.73 | -$3.01 | -$4.36 |
| Operating cash flow | -$48.1M | -$69.5M | -$101.0M | -$151.1M | -$181.4M | -$279.1M |
| Free cash flow | -$50.8M | -$71.6M | -$103.9M | -$156.7M | -$184.5M | -$279.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -97.3% | -428.4% | -1368.9% | — | — | -4974.3% |
| Net margin | -89.7% | -427.8% | -1328.9% | — | — | -4612.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $7.5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$69.1M | -$73.7M | -$77.5M | -$72.7M | -$94.2M | -$96.3M | -$109.8M | -$112.3M |
| Net income | -$57.9M | -$62.8M | -$65.7M | -$65.0M | -$84.7M | -$90.9M | -$105.3M | -$102.3M |
| Diluted EPS | -$0.75 | -$0.81 | -$0.83 | -$0.83 | -$1.07 | -$1.15 | -$1.31 | -$1.17 |
| Operating cash flow | -$31.2M | -$49.7M | -$54.4M | -$61.7M | -$64.2M | -$71.8M | -$81.5M | -$88.9M |
| Free cash flow | -$32.7M | -$50.3M | -$55.2M | -$61.7M | -$64.4M | -$72.0M | -$81.8M | -$89.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | -969.8% | — | — | — | — |
| Net margin | — | — | — | -867.3% | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-05 | PATOU GARY | Sale | 1,322 | $53.14 | $70,251.08 | filing |
| 2026-06-05 | Cannon Gillian | Sale | 1,190 | $53.14 | $63,236.60 | filing |
| 2026-06-01 | GANNON STEVEN | Tax withholding | 1,416 | $53.41 | $75,628.56 | filing |
| 2026-06-01 | Svoronos Dawn | Tax withholding | 1,416 | $53.41 | $75,628.56 | filing |
| 2026-06-01 | Machado Patrick | Option exercise | 2,645 | — | — | filing |
| 2026-06-01 | GAROFALO ELIZABETH A. | Option exercise | 2,645 | — | — | filing |
| 2026-06-01 | GANNON STEVEN | Option exercise | 2,645 | — | — | filing |
| 2026-06-01 | Svoronos Dawn | Option exercise | 2,645 | — | — | filing |
| 2026-06-01 | PATOU GARY | Option exercise | 2,645 | — | — | filing |
| 2026-06-01 | Gover Justin D. | Option exercise | 2,645 | — | — | filing |
| 2026-06-01 | Cannon Gillian | Option exercise | 2,645 | — | — | filing |
| 2026-05-12 | GANNON STEVEN | Option exercise | 3,500 | $7.38 | $25,830.00 | filing |
| 2026-03-13 | MORTIMER IAN· PRESIDENT & CEO | Sale | 7,308 | $55.23 | $403,584.30 | filing |
| 2026-03-13 | KENNEY CHRISTOPHER JOHN· Chief Medical Officer | Sale | 1,410 | $55.23 | $77,867.25 | filing |
| 2026-03-13 | DiFabio Andrea· Chief Legal Officer | Sale | 1,342 | $55.23 | $74,111.95 | filing |
| 2026-03-12 | KENNEY CHRISTOPHER JOHN· Chief Medical Officer | Option exercise | 3,750 | — | — | filing |
| 2026-03-12 | DiFabio Andrea· Chief Legal Officer | Option exercise | 3,750 | — | — | filing |
| 2026-03-12 | MORTIMER IAN· PRESIDENT & CEO | Option exercise | 12,500 | — | — | filing |
| 2026-01-02 | MORTIMER IAN· PRESIDENT & CEO | Sale | 37,938 | $44.40 | $1.7M | filing |
| 2026-01-02 | MORTIMER IAN· PRESIDENT & CEO | Option exercise | 40,000 | $7.49 | $299,600.00 | filing |
| 2026-01-02 | MORTIMER IAN· PRESIDENT & CEO | Sale | 2,062 | $44.93 | $92,645.66 | filing |
| 2025-12-08 | MORTIMER IAN· PRESIDENT & CEO | Sale | 8,820 | $45.59 | $402,103.80 | filing |
| 2025-12-08 | MORTIMER IAN· PRESIDENT & CEO | Sale | 2,010 | $46.32 | $93,103.20 | filing |
| 2025-12-05 | MORTIMER IAN· PRESIDENT & CEO | Sale | 14,375 | $45.03 | $647,306.25 | filing |
| 2025-11-28 | MORTIMER IAN· PRESIDENT & CEO | Sale | 97 | $45.01 | $4,365.97 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.